Drug Profile


Alternative Names: MRZ 3124

Latest Information Update: 27 Jun 2001

Price : $50

At a glance

  • Originator Merz Pharma
  • Class Antihyperlipidaemics; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Cholesterol inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Reperfusion injury

Most Recent Events

  • 27 Jun 2001 Discontinued-I for Reperfusion injury in Germany (Unknown route)
  • 27 Jun 2001 Discontinued-I for Atherosclerosis in Germany (Unknown route)
  • 05 Mar 1999 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top